Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Avinger Inc.SCHEDULE 13G/A - Avinger Inc (0001506928) (Subject)
- SECAvinger Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Changes in Registrant's Certifying Accountant, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Avinger Inc (0001506928) (Filer)
- SECAvinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Avinger Inc (0001506928) (Filer)
- INSIDERVice President, Finance Subainati Nabeel Paul sold $699 worth of shares (1,255 units at $0.56), decreasing direct ownership by 28% to 3,296 units (SEC Form 4)4 - Avinger Inc (0001506928) (Issuer)
- INSIDERChief Executive Officer Soinski Jeffrey M sold $2,054 worth of shares (3,690 units at $0.56), decreasing direct ownership by 6% to 55,265 units (SEC Form 4)4 - Avinger Inc (0001506928) (Issuer)
- INSIDERChief Technology Officer Patel Himanshu sold $1,233 worth of shares (2,215 units at $0.56), decreasing direct ownership by 5% to 39,062 units (SEC Form 4)4 - Avinger Inc (0001506928) (Issuer)
- SECSEC Form DEFA14A filed by Avinger Inc.DEFA14A - Avinger Inc (0001506928) (Filer)
- SECAvinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Avinger Inc (0001506928) (Filer)
- SECSEC Form 144 filed by Avinger Inc.144 - Avinger Inc (0001506928) (Subject)
- SECAvinger Inc. filed SEC Form 8-K: Other Events8-K - Avinger Inc (0001506928) (Filer)
- SECAvinger Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Avinger Inc (0001506928) (Filer)
- SECSEC Form DEF 14A filed by Avinger Inc.DEF 14A - Avinger Inc (0001506928) (Filer)
- SECAvinger Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Avinger Inc (0001506928) (Filer)
- SECAvinger Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Avinger Inc (0001506928) (Filer)
- SECAvinger Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Other Events8-K - Avinger Inc (0001506928) (Filer)
- SECSEC Form PRE 14A filed by Avinger Inc.PRE 14A - Avinger Inc (0001506928) (Filer)
- SECAvinger Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Avinger Inc (0001506928) (Filer)
- 13D/GSEC Form SC 13G filed by Avinger Inc.SC 13G - Avinger Inc (0001506928) (Subject)
- 13D/GAmendment: SEC Form SC 13G/A filed by Avinger Inc.SC 13G/A - Avinger Inc (0001506928) (Subject)
- SECAvinger Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Avinger Inc (0001506928) (Filer)
- SECSEC Form 10-Q filed by Avinger Inc.10-Q - Avinger Inc (0001506928) (Filer)
- PRAvinger Reports Third Quarter 2024 ResultsLower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development
- SECSEC Form DEFA14A filed by Avinger Inc.DEFA14A - Avinger Inc (0001506928) (Filer)
- SECSEC Form DEF 14A filed by Avinger Inc.DEF 14A - Avinger Inc (0001506928) (Filer)
- PRAvinger to Announce Third Quarter 2024 Results on November 7, 2024REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co
AVGR FAQ
7 questionsWhat does Avinger Inc. do?
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed...Where does AVGR stock trade?
Avinger Inc. (AVGR) is listed on NASDAQ.What sector and industry is AVGR in?
Avinger Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Avinger Inc. go public?
Avinger Inc. (AVGR) completed its IPO in 2015.What are analysts saying about AVGR?
Avinger Inc. has had 2 recent analyst actions on file. The most recent action was from Aegis Capital: Buy with a $200.00 price target on 2021-11-15. Recent price targets range from $200.00 to $250.00.What companies are similar to AVGR?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare AVGR side-by-side with any of them on Quantisnow.How can I track AVGR on Quantisnow?
Quantisnow aggregates Avinger Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVGR to receive live email and push alerts on every new disclosure.